HOUSTON, Aug. 7, 2023
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX)
(Moleculin or the Company), a clinical stage pharmaceutical
company with a broad portfolio of drug candidates targeting
hard-to-treat tumors and viruses, today announced that it is
investigating potential naked short selling of its stock and has
retained well-known analytics firm, Shareholder Intelligence
Services, LLC ("ShareIntel"). ShareIntel's investigation will
provide shareholder data, including share ownership, purchases,
sales and custody by individuals, institutions, broker-dealers,
clearing agents and custodians, and other information related to
the Company's public shareholders and market activity with respect
to sales of publicly traded common stock.
![Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. (PRNewsfoto/Moleculin Biotech, Inc.) Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. (PRNewsfoto/Moleculin Biotech, Inc.)](https://mma.prnewswire.com/media/959635/Moleculin_Biotech_Inc_Logo.jpg)
"We value our shareholders and believe that the information
ShareIntel can provide gives us all available data at our disposal
to act in our fiduciary capacity. We are grateful for the continued
support of our loyal shareholders and the support for our ongoing
clinical development programs. We now have the tools in place to
analyze trading patterns of our common stock and mitigate any
illegal or otherwise prohibited trading activity, including
potential naked short selling, should any such activities be
discovered," commented Walter Klemp,
Chairman and Chief Executive Officer of Moleculin.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company with a growing pipeline, including Phase 2 clinical
programs, for hard-to-treat tumors and viruses. The Company's lead
program, Annamycin is a next-generation anthracycline designed to
avoid multidrug resistance mechanisms with little to no
cardiotoxicity. Annamycin is currently in development for the
treatment of relapsed or refractory acute myeloid leukemia (AML)
and soft tissue sarcoma (STS) lung metastases.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in the development of a portfolio of antimetabolites, including
WP1122 for the potential treatment of COVID-19 and other viruses,
as well as cancer indications including brain tumors, pancreatic
and other cancers.
For more information about the Company, please visit
www.moleculin.com and connect on Twitter, LinkedIn and
Facebook.
About Shareholder Intelligence Services, LLC
Shareintel is a patented compliance driven SAAS retained by
public companies to track shareholder ownership and monitor
broker-dealer and shareholder movement. DRIL-Down™ identifies
participants to potential abusive and illegal short selling
providing actionable intelligence. For more information,
visit www.shareintel.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the results of the review of
the trading activity in the Company's common stock.
Although Moleculin believes that the expectations reflected in
such forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Moleculin has attempted to identify forward-looking statements by
terminology including 'believes,' 'estimates,' 'anticipates,'
'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,'
'could,' 'might,' 'will,' 'should,' 'approximately' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under Item 1A. "Risk
Factors" in our most recently filed Form 10-K filed with the
Securities and Exchange Commission ("SEC") and updated from time to
time in our Form 10-Q filings and in our other public filings with
the SEC. Any forward-looking statements contained in this release
speak only as of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-retains-shareholder-intelligence-services-llc-to-investigate-potential-naked-short-selling-301894203.html
SOURCE Moleculin Biotech, Inc.